Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Proactive news snapshot: Sirius Minerals, Cradle Arc, Pan African Resources …

A glance at some of the day's highlights from the Proactive Investors newswire
Your daily round-up from the world of Proactive

Sirius Minerals PLC (LON:SXX) has struck a new U$250mln funding deal which it expects will bridge the gap until Stage 2 project financing is needed, in the second quarter of 2019. Specifically, Sirius has agreed an amendment to an agreement with Hancock British Holdings Ltd, originally made in 2016.

Cradle Arc Plc (LON:CRA) has renewed prospecting licenses for an area north of its Mowana copper mine in Botswana.

Pan African Resources plc (LON:PAF) told investors that it is looking forward to the year ahead, following a period which saw a challenging operating environment. In the company’s trading statement for the financial year, ended June 30, chief executive Cobus Loots said: “The group results for the 2018 financial year are reflective of both the incredibly challenging operational environment and the specific issues that confronted the group over the past year.

Kibo Energy (LON:KIBO) reported significantly reduced first-half operating losses and said the company had made good progress in expanding its portfolio and had solidified its position in the African energy market.

ECR Minerals PLC (LON:ECR) told investors it has restarted its exploration programme at the Bailieston project, Central Victoria, Australia. The company noted that it has identified eight targets across its five exploration areas, and, an exploration programme has been designed to test surface gold mineralisation.

ValiRx Plc (LON:VAL), the clinical stage biotechnology company, has raised £1.15mln via a placing to accelerate its clinical and pre-clinical portfolio, welcoming new investors in the process. The AIM-listed firm said it issued 76,666,666 new ordinary shares at a price of 1.50p each in the placing undertaken by the company's broker, Novum Securities.

Summit Therapeutics PLC (LON:SUMM) (NASDAQ:SMMT) has announced that its management will participate in one on one meetings for two upcoming investor conferences in New York City – the Janney Healthcare Conference on 17 September 2018, and the Oppenheimer Fall Summit on 26 September 2018. The biotech group also said it will announce its financial results for the second quarter and half year ended 31 July 2018 on 20 September.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use